Autors:

CiteWeb id: 20120000897

CiteWeb score: 630

DOI: 10.1056/NEJMoa1209979

In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the patients in the moni - toring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval (CI), 0.98 to 1.29; P = 0.10). The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional- treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P = 0.77). The rate of major bleeding events did not differ significantly between groups. CONCLUSIONS This study showed no significant improvements in clinical outcomes with platelet- function monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatelet therapy without monitoring. (Funded by Allies in Cardiovas -

The publication "Bedside monitoring to adjust antiplatelet therapy for coronary stenting." is placed in the Top 1000 in 2012.
Links to full text of the publication: